VDN | Vaccine Pipeline
Sponsor & Developer Portfolio

CanSino Biologics

Clinical development pipeline, platform architecture, and registered trial tracking for CanSino Biologics vaccine candidates.

11
Candidates
7
Target Diseases
17
Linked Studies

Development Phase Distribution

Phase 3 Clinical Trial: 5 Discontinued / Inactive: 2 Phase 2 Clinical Trial: 2 Phase 1 Clinical Trial: 2

Platform Technologies

Conjugate vaccine: 5 Biological (unspecified platform): 3 Viral vector: 1 mRNA: 1 Virus-like particle: 1

Target Pathogens & Indications

COVID-19 Diphtheria / Tetanus / Pertussis Epidemic Meningitis Influenza Meningococcal disease Pneumococcal disease Polio

Vaccine Pipeline Candidates (11)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

Discontinued / Inactive ctgov-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-c

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Target: COVID-19

Platform: Viral vector

Key Milestone: Primary completion (most advanced trial): 2023-01-13 (registry estimate)
View Full Clinical Profile → Disease Hub →
Discontinued / Inactive ctgov-bivalent-recombinant-covid-19-vaccine-adenovirus-type-5-vector-c

mRNA-based COVID-19 vaccine

Target: COVID-19

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2023-03-30 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 1 Clinical Trial ctgov-adsorbed-acellular-pertussis-3-component-diphtheria-tetanus-pert

DTcP-Hib-MCV4

Target: Influenza

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2029-02 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 1 Clinical Trial ctgov-lyophilized-haemophilus-influenzae-type-b-conjugate-vaccine-cans

Haemophilus Influenzae Type b Conjugate Vaccine

Target: Influenza

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2026-10 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 2 Clinical Trial ctgov-24-valent-pneumococcal-polysaccharide-conjugate-vaccine-crm197-t

PCV24 vaccine (dose H)

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2026-11-24 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 2 Clinical Trial ctgov-recombinant-trivalent-poliomyelitis-vaccine-sf-rvn-cell-vlp-poli

VLP-Polio medium dose

Target: Polio

Platform: Virus-like particle

Key Milestone: Primary completion (most advanced trial): 2026-10 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-tetanus-reduced-diphtheria-and-acellular-pertussis-five-componen

23-valent Pneumococcal Polysaccharide Vaccine (PPV23)

Target: Diphtheria / Tetanus / Pertussis

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2025-05-30 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-diphtheria-tetanus-and-acellular-pertussis-three-components-comb

Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP

Target: Diphtheria / Tetanus / Pertussis

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2025-04-01 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-mcv4-cansino-biologics-inc

MCV4

Target: Epidemic Meningitis

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2025-12 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-pcv13i-cansino-biologics-inc

PCV13i

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-02-15 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-batch-1-of-group-acyw135-meningococcal-conjugate-vaccine-crm197-

batch 2 of MCV4

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2024-07-12 (registry estimate)
View Full Clinical Profile → Disease Hub →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →